Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)36.56m
- Net income in DKK-86.80m
- Incorporated1917
- Employees48.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mentice AB | 194.00m | -30.61m | 264.38m | 121.00 | -- | 2.97 | -- | 1.36 | -1.68 | -1.68 | 10.52 | 4.48 | 0.9663 | 1.60 | 3.94 | 2,095,328.00 | -15.25 | -6.64 | -31.60 | -11.91 | 90.40 | 84.80 | -15.78 | -8.53 | 0.845 | -30.10 | 0.116 | -- | 6.11 | 14.22 | -553.89 | -- | 32.86 | -- |
| Ortoma AB | 54.55m | -5.31m | 327.93m | 10.00 | -- | 2.95 | 88.86 | 6.01 | -0.2027 | -0.2027 | 2.08 | 4.45 | 0.4243 | 3.95 | 39.13 | 7,530,537.00 | -4.13 | -9.37 | -4.45 | -10.43 | 41.26 | 158.24 | -9.74 | -78.90 | 3.02 | -- | 0.00 | -- | 28.77 | -- | 46.83 | -- | -0.5751 | -- |
| Q linea AB | 7.84m | -128.97m | 328.11m | 83.00 | -- | 1.37 | -- | 41.83 | -35.87 | -35.87 | 1.31 | 17.84 | 0.0429 | 0.4006 | 2.90 | -- | -70.50 | -76.00 | -101.81 | -93.84 | -15.26 | -145.47 | -1,644.30 | -2,820.51 | 10.04 | -30.48 | 0.017 | -- | 369.86 | 114.75 | 15.86 | -- | -34.47 | -- |
| Bactiguard Holding AB | 161.68m | -5.54m | 349.95m | 153.00 | -- | 1.77 | 12.62 | 2.16 | -0.2238 | -0.2238 | 6.53 | 8.99 | 0.381 | 3.44 | 6.91 | 1,495,216.00 | -1.31 | -8.02 | -1.86 | -10.13 | 63.78 | 48.56 | -3.43 | -25.10 | 1.38 | -0.3387 | 0.3410 | -- | -12.64 | 4.22 | 73.69 | -- | -17.92 | -- |
| Modulight Oyj | 50.54m | -34.46m | 355.98m | 71.00 | -- | 1.05 | -- | 7.04 | -0.1172 | -0.1172 | 0.1727 | 1.07 | 0.1254 | -0.7943 | 4.78 | 102,484.90 | -8.55 | -9.90 | -9.25 | -10.66 | 129.94 | 119.43 | -68.15 | -88.50 | 3.46 | -- | 0.081 | -- | 1.74 | -10.65 | 45.65 | -- | 24.38 | -- |
| Nanexa AB | 7.47m | -27.60m | 433.30m | 15.00 | -- | 7.64 | -- | 57.97 | -0.2644 | -0.2644 | 0.0694 | 0.4874 | 0.0972 | 24.67 | 1.54 | 813,538.40 | -35.91 | -37.21 | -42.59 | -44.95 | 69.56 | 93.79 | -369.29 | -355.05 | 2.07 | -21.98 | 0.2165 | -- | -16.93 | 70.11 | 67.40 | -- | 21.42 | -- |
| Optomed Oyj | 129.87m | -42.92m | 473.65m | 112.00 | -- | 2.87 | -- | 3.65 | -0.2915 | -0.2915 | 0.8803 | 1.03 | 0.5847 | 2.40 | 5.47 | 151,147.80 | -19.33 | -14.59 | -23.47 | -17.41 | 64.64 | 65.60 | -33.05 | -31.36 | 1.60 | -20.89 | 0.1221 | -- | -0.3974 | 0.084 | -22.72 | -- | 8.10 | -- |
| OssDsign AB | 127.33m | -36.04m | 473.80m | 32.00 | -- | 2.16 | -- | 3.72 | -0.5493 | -0.5493 | 2.06 | 2.80 | 0.5109 | 0.3672 | 6.95 | 5,629,938.00 | -14.46 | -25.42 | -16.05 | -28.59 | 96.29 | 85.57 | -28.30 | -82.42 | 6.33 | -13.77 | 0.0044 | -- | 34.51 | 48.59 | -2.68 | -- | 24.28 | -- |
| BioPorto A/S | 36.56m | -86.80m | 491.15m | 48.00 | -- | 12.82 | -- | 13.43 | -0.1973 | -0.1973 | 0.083 | 0.0774 | 0.4132 | 2.55 | 4.69 | 962,131.60 | -98.08 | -65.22 | -133.92 | -88.74 | 63.90 | 64.15 | -237.40 | -222.22 | 1.71 | -- | 0.1916 | -- | 17.07 | 6.36 | -21.15 | -- | -20.56 | -- |
| Senzime AB (publ) | 63.40m | -85.25m | 503.89m | 50.00 | -- | 2.05 | -- | 7.95 | -0.8672 | -0.8672 | 0.6394 | 2.22 | 0.234 | 1.73 | 5.99 | 1,794,120.00 | -31.47 | -35.09 | -34.04 | -37.52 | 41.86 | 8.75 | -134.46 | -400.65 | 4.30 | -7.70 | 0.0399 | -- | 63.55 | 54.18 | 11.50 | -- | 40.12 | -- |
| Omda AS | 313.27m | -19.97m | 579.17m | 260.00 | -- | 25.79 | 29.62 | 1.85 | -1.51 | -1.51 | 23.59 | 1.63 | 0.6793 | 26.59 | 21.70 | 1,772,075.00 | -4.33 | -5.14 | -5.39 | -6.63 | 93.69 | 91.09 | -6.37 | -10.32 | 0.6483 | 0.5281 | 0.9359 | -- | 3.45 | 15.80 | -163.95 | -- | -15.57 | -- |
| Gentian Diagnostics ASA | 113.80m | 28.22m | 590.04m | 63.00 | 21.21 | 4.43 | 17.26 | 5.18 | 2.73 | 2.73 | 11.07 | 13.10 | 0.8181 | 1.63 | 7.83 | 2,738,365.00 | 20.29 | -2.99 | 22.99 | -3.36 | 55.06 | 44.66 | 24.80 | -5.84 | 4.16 | -- | 0.0094 | -- | 12.52 | 25.96 | 525.37 | -- | 22.08 | -- |
| Nexstim Oyj | 75.20m | -2.11m | 644.04m | 40.00 | -- | 27.00 | 129.87 | 8.56 | -0.042 | -0.042 | 1.47 | 0.4426 | 0.8553 | 0.5613 | 4.66 | 251,616.80 | -2.40 | -12.40 | -4.17 | -20.76 | 94.36 | 95.09 | -2.81 | -16.29 | 1.08 | 0.7835 | 0.6002 | -- | 20.55 | 21.14 | 32.79 | -- | 15.13 | -- |
| Sedana Medical AB (publ) | 139.66m | -28.73m | 701.37m | 117.00 | -- | 1.09 | -- | 5.02 | -0.4092 | -0.4092 | 1.99 | 9.14 | 0.2012 | 1.46 | 9.47 | 2,670,406.00 | -4.14 | -4.90 | -4.34 | -5.16 | 70.47 | 68.32 | -20.57 | -30.26 | 3.28 | -21.90 | 0.0045 | -- | 16.17 | 20.06 | 82.09 | -- | 26.45 | -- |
Data as of Feb 11 2026. Currency figures normalised to Bioporto A/S's reporting currency: Danish Krone DKK
0.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 30 Nov 2025 | 1.21m | 0.25% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 114.42k | 0.02% |
| AL Sydbank A/S (Investment Management)as of 31 Dec 2025 | 89.27k | 0.02% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 73.51k | 0.02% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
